Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
1999 1
2000 2
2001 1
2002 2
2005 2
2007 1
2009 1
2011 4
2012 3
2017 2
2019 1
2021 1
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

23 results
Results by year
Filters applied: . Clear all
Page 1
Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model.
Yang T, Poenisch M, Khanal R, Hu Q, Dai Z, Li R, Song G, Yuan Q, Yao Q, Shen X, Taubert R, Engel B, Jaeckel E, Vogel A, Falk CS, Schambach A, Gerovska D, Araúzo-Bravo MJ, Vondran FWR, Cantz T, Horscroft N, Balakrishnan A, Chevessier F, Ott M, Sharma AD. Yang T, et al. Among authors: horscroft n. J Hepatol. 2021 Dec;75(6):1420-1433. doi: 10.1016/j.jhep.2021.08.011. Epub 2021 Aug 25. J Hepatol. 2021. PMID: 34453962 Free article.
mRNA mediates passive vaccination against infectious agents, toxins, and tumors.
Thran M, Mukherjee J, Pönisch M, Fiedler K, Thess A, Mui BL, Hope MJ, Tam YK, Horscroft N, Heidenreich R, Fotin-Mleczek M, Shoemaker CB, Schlake T. Thran M, et al. Among authors: horscroft n. EMBO Mol Med. 2017 Oct;9(10):1434-1447. doi: 10.15252/emmm.201707678. EMBO Mol Med. 2017. PMID: 28794134 Free PMC article.
Antiviral applications of Toll-like receptor agonists.
Horscroft NJ, Pryde DC, Bright H. Horscroft NJ, et al. J Antimicrob Chemother. 2012 Apr;67(4):789-801. doi: 10.1093/jac/dkr588. Epub 2012 Jan 18. J Antimicrob Chemother. 2012. PMID: 22258929 Review.
mRNA as a Novel Treatment Strategy for Hereditary Spastic Paraplegia Type 5.
Hauser S, Poenisch M, Schelling Y, Höflinger P, Schuster S, Teegler A, Betten R, Gustafsson JÅ, Hübener-Schmid J, Schlake T, Chevessier-Tünnesen F, Horscroft N, Björkhem I, Schöls L. Hauser S, et al. Among authors: horscroft n. Mol Ther Methods Clin Dev. 2019 Oct 31;15:359-370. doi: 10.1016/j.omtm.2019.10.011. eCollection 2019 Dec 13. Mol Ther Methods Clin Dev. 2019. PMID: 31828178 Free PMC article.
Discovery of a highly potent series of TLR7 agonists.
Jones P, Pryde DC, Tran TD, Adam FM, Bish G, Calo F, Ciaramella G, Dixon R, Duckworth J, Fox DN, Hay DA, Hitchin J, Horscroft N, Howard M, Laxton C, Parkinson T, Parsons G, Proctor K, Smith MC, Smith N, Thomas A. Jones P, et al. Among authors: horscroft n. Bioorg Med Chem Lett. 2011 Oct 1;21(19):5939-43. doi: 10.1016/j.bmcl.2011.07.076. Epub 2011 Aug 4. Bioorg Med Chem Lett. 2011. PMID: 21885277
An infection-based model of neurodevelopmental damage.
Hornig M, Weissenböck H, Horscroft N, Lipkin WI. Hornig M, et al. Among authors: horscroft n. Proc Natl Acad Sci U S A. 1999 Oct 12;96(21):12102-7. doi: 10.1073/pnas.96.21.12102. Proc Natl Acad Sci U S A. 1999. PMID: 10518583 Free PMC article.
Preclinical studies of PF-04849285, an interferon-α8 fusion protein for the treatment of HCV.
Flores MV, Hickling TP, Sreckovic S, Fidock MD, Horscroft N, Katragadda M, Savic B, Rawal J, Delpuech-Adams OE, Robas N, Corey T, Nelms L, Lawton M, Marcek J, Stubbs M, Westby M, Ciaramella G. Flores MV, et al. Among authors: horscroft n. Antivir Ther. 2012;17(5):869-81. doi: 10.3851/IMP2099. Epub 2012 Apr 13. Antivir Ther. 2012. PMID: 22505586
Corrigendum to 'Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model' [J Hepatol (2021) 1420-1433].
Yang T, Poenisch M, Khanal R, Hu Q, Dai Z, Li R, Song G, Yuan Q, Yao Q, Shen X, Taubert R, Engel B, Jaeckel E, Vogel A, Falk CS, Schambach A, Gerovska D, Araúzo-Bravo MJ, Vondran FWR, Cantz T, Horscroft N, Balakrishnan A, Chevessier F, Ott M, Sharma AD. Yang T, et al. Among authors: horscroft n. J Hepatol. 2022 Apr 7:S0168-8278(22)00197-0. doi: 10.1016/j.jhep.2022.03.023. Online ahead of print. J Hepatol. 2022. PMID: 35397937 No abstract available.
23 results